Teva Non Currrent Assets Other from 2010 to 2024

TEVA Stock  USD 16.25  0.25  1.56%   
Teva Pharma's Non Currrent Assets Other are decreasing over the years with slightly volatile fluctuation. Overall, Non Currrent Assets Other are expected to go to about 594.6 M this year. Non Currrent Assets Other is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. View All Fundamentals
 
Non Currrent Assets Other  
First Reported
1986-03-31
Previous Quarter
462 M
Current Value
471 M
Quarterly Volatility
623.2 M
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva main balance sheet or income statement drivers, such as Depreciation And Amortization of 667.3 M, Interest Expense of 1.1 B or Total Revenue of 9.5 B, as well as many exotic indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.0042 or PTB Ratio of 1.48. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.
  
This module can also supplement Teva Pharma's financial leverage analysis and stock options assessment as well as various Teva Pharma Technical models . Check out the analysis of Teva Pharma Correlation against competitors.

Latest Teva Pharma's Non Currrent Assets Other Growth Pattern

Below is the plot of the Non Currrent Assets Other of Teva Pharma Industries over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Teva Pharma's Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teva Pharma's overall financial position and show how it may be relating to other accounts over time.
Non Currrent Assets Other10 Years Trend
Slightly volatile
   Non Currrent Assets Other   
       Timeline  

Teva Non Currrent Assets Other Regression Statistics

Arithmetic Mean815,372,410
Geometric Mean621,228,442
Coefficient Of Variation51.39
Mean Deviation358,719,084
Median673,000,000
Standard Deviation418,993,367
Sample Variance175555.4T
Range1.5B
R-Value(0.44)
Mean Square Error151767.6T
R-Squared0.20
Significance0.1
Slope(41,610,346)
Total Sum of Squares2457776.2T

Teva Non Currrent Assets Other History

2024594.6 M
2023462 M
2022441 M
2021515 M
2020538 M
2019591 M
2018673 M

About Teva Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Teva Pharma income statement, its balance sheet, and the statement of cash flows. Teva Pharma investors use historical funamental indicators, such as Teva Pharma's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may use each financial statement separately, they are all related. The changes in Teva Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Teva Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Teva Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Teva Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Currrent Assets Other462 M594.6 M

Currently Active Assets on Macroaxis

When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Check out the analysis of Teva Pharma Correlation against competitors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Teva Stock analysis

When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.42)
Revenue Per Share
14.277
Quarterly Revenue Growth
0.043
Return On Assets
0.0484
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.